CNBX PHARMACEUTICALS INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CNBX PHARMACEUTICALS INC. (CNBX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$11.30 thousand for the 12-month period ending 2025-08-31, per its 10-K filed 2025-12-01.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-12-01
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-11-30 was -$48.05K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-11-30 was -$95.92K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-11-30 was -$600.06K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-11-30 was -$593.58K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$11.30K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$103.28K, a 947.88% decline from fiscal 2023.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $12.18K.
- CNBX PHARMACEUTICALS INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$1.26M, a 307.62% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-08-31 | -$11.30K 10-K · filed 2025-12-01 | |||
| 2024-08-31 | -$103.28K 10-K · filed 2025-12-01 | |||
| 2023-11-30 | -$48.05K 10-Q · filed 2024-01-12 | |||
| 2023-08-31 | $12.18K 10-K · filed 2024-11-29 | |||
| 2023-02-28 | -$69.77K 10-Q · filed 2023-04-14 | |||
| 2022-11-30 | -$95.92K 10-Q · filed 2024-01-12 | |||
| 2022-08-31 | -$1.26M 10-K · filed 2023-11-30 | |||
| 2022-02-28 | -$1.15M 10-Q · filed 2023-04-14 | |||
| 2021-11-30 | -$600.06K 10-Q · filed 2023-01-13 | |||
| 2021-08-31 | $608.86K 10-K · filed 2022-11-30 | |||
| 2021-05-31 | $1.19M 10-Q · filed 2021-07-14 | |||
| 2021-02-28 | $556.80K 10-Q · filed 2022-04-12 | |||
| 2020-11-30 | -$593.58K 10-Q · filed 2022-01-13 | |||
| 2020-08-31 | $511.63K 10-K · filed 2021-11-29 | |||
| 2020-05-31 | $91.65K 10-Q · filed 2021-07-14 | |||
| 2020-02-29 | $320.99K 10-Q · filed 2021-04-14 |